Moss, R. B., Flume, P. A., Elborn, J. S., Cooke, J., Rowe, S. M., McColley, S. A., . . . Higgins, M. (2015). Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial. The lancet respiratory medicine, 3(7), 524-533. https://doi.org/10.1016/S2213-2600(15)00201-5
Citace podle Chicago (17th ed.)Moss, Richard B., Patrick A. Flume, J Stuart Elborn, Jon Cooke, Steven M. Rowe, Susanna A. McColley, Ronald C. Rubenstein, a Mark Higgins. "Efficacy and Safety of Ivacaftor in Patients with Cystic Fibrosis Who Have an Arg117His-CFTR Mutation: A Double-blind, Randomised Controlled Trial." The Lancet Respiratory Medicine 3, no. 7 (2015): 524-533. https://doi.org/10.1016/S2213-2600(15)00201-5.
Citace podle MLA (9th ed.)Moss, Richard B., et al. "Efficacy and Safety of Ivacaftor in Patients with Cystic Fibrosis Who Have an Arg117His-CFTR Mutation: A Double-blind, Randomised Controlled Trial." The Lancet Respiratory Medicine, vol. 3, no. 7, 2015, pp. 524-533, https://doi.org/10.1016/S2213-2600(15)00201-5.